BACKGROUND: Mutations in the colony-stimulating factor 3 receptor (CSF3R) gene occur frequently in chronic neutrophilic leukemia and are rare in de novo acute leukemia.The objective of this study was to assess the incidence of CSF3R mutations in acute leukemia and their association with other genetic abnormalities. METHODS: Amplicon-targeted, next-generation sequencing of 58 genes was performed retrospectively on 1152 patients (acute myeloid leukemia [AML], n 5 587; acute lymphoid leukemia [ALL], n 5 565). Reverse transcriptasepolymerase chain reaction analysis was used to detect 35 leukemia-specific gene fusions. RESULTS: CSF3R mutations (26 patients) were detected in 3.6% (13 of 364 patients), 4.6% (8 of 175 patients), and 8.3% (4 of 48 patients) of those with de novo, relapsed, and secondary AML, respectively, and in 0.2% (1 of 565 patients) of those with ALL. In total, 9 distinct CSF3R mutations were detected. Membrane-proximal missense mutations and cytoplasmic truncations were identified as mutually exclusive. The proportion of patients who had French-American-British subtypes M2 and M4 in the CSF3R-mutated group was significantly greater than that in the CSF3R wild-type group for both the de novo AML cohort (P 5.001) and the relapsed AML cohort (P 5.024). All de novo and relapsed AMLs with CSF3R mutations were associated with genetic alterations in transcription factors, including RUNX1-RUNX1T1, CBFB-
INTRODUCTION
The CSF3R gene encodes the colony-stimulating factor 3 receptor, which is essential for the production, differentiation, and function of granulocytes. CSF3R mutations occur in approximately 83% of patients with chronic neutrophilic leukemia (CNL) and serve as a specific diagnostic marker for CNL. 1 Somatic mutations of CSF3R primarily result in T618I and T615A amino acid substitutions in the membrane-proximal region (leading to ligand-independent receptor activation) or cytoplasmic domain truncations (causing CSF3R overexpression and hypersensitivity to ligand). CSF3R mutations in membrane-proximal and cytoplasmic regions can result in sustained activation of the Janus kinase (JAK) and SRC-family tyrosine kinase nonreceptor 2 (TNK2) kinase pathways, respectively, and can be blocked by kinase inhibitors.
2 CSF3R mutations also are identified in approximately 30% of patients who have severe congenital neutropenia (SCN) 3, 4 and other hematologic malignancies, including atypical chronic myeloid leukemia (aCML), chronic myelomonocytic leukemia, acute myeloid leukemia (AML), and early T-cell precursor lymphoblastic leukemia, 2 but are rarely observed in patients with B-cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia, essential thrombocythemia, and other diseases.
CSF3R mutations are uncommon in AML and have been reported in 3% of patients who have an intermediate-risk AML karyotype, in 1.9% to 3.6% of patients with pediatric AML, and in 1% of adults with AML. 2, 6, 7 Although it is relatively rare, CSF3R mutations often are associated with doublemutated CCAAT/enhancer binding protein a (CEBPAdm). 5, 7 In the current study, we retrospectively analyzed 1152 patients with acute leukemia and evaluated the frequency of CSF3R mutations and their associated genetic abnormalities.
MATERIALS AND METHODS

Patients
We studied 1152 patients with acute leukemia who received treatment at Hebei Yanda Lu Daopei Hospital. The patient population consisted of 587 patients with AML (364 de novo, 175 relapsed, and 48 secondary AML; 336 males and 251 females; median age, 24 years; age range, 1-75 years) and 565 patients with ALL (257 de novo and 225 relapsed B-ALL, 52 de novo and 31 relapsed Tcell ALL [T-ALL]; 349 males and 216 females; median age, 11.5 years; age range, 1-83 years). The diagnoses of AML and ALL were made according to the World Health Organization (WHO) 2008 classification of myeloid neoplasms and acute leukemia. 8 The study was approved by our Institutional Review Board and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants.
Sample Preparation
Bone marrow (including bone marrow smear specimens) and/or peripheral blood samples were collected. Nucleated cells (1.0 3 10 7 ) of fresh bone marrow and peripheral blood samples were used for genomic DNA extraction. Bone marrow smear specimens were repeatedly pipetted with pure water, and the resultant cell suspension was used for genomic DNA extraction using the silica column extraction method. Nucleated cells (5.0 3 10 6 ) were used for total RNA extraction using the TRIzol reagent method (Thermo Fisher Scientific, Waltham, MA).
DNA Sequencing and Mutation Analysis
We sequenced the mutational hotspots or whole coding regions of 58 genes (Supporting Table 1 ) that are known to be frequently mutated in hematologic malignancies using a targeted, multiplexed, amplicon-based, high-throughput sequencing protocol (Ion Torrent PGM; Thermo Fisher Scientific). The average sequencing depth was 1000x. Single nucleotide variants and short insertions or deletions (InDels) were called using Torrent Variant Caller (TVC 5.0-13; Thermo Fisher Scientific). A minimum coverage of 100 and a variant allele frequency (VAF) > 5% were used as thresholds for calling single nucleotide variants. Sequence variants were functionally annotated using ANNOVAR 9 and SnpEff. 10 All variants with a population minor allele frequency >1% were filtered.
The mutation hotspot regions of exons 14 and 17 of CSF3R were analyzed according to transcript NM_000760.3. InDels of Fms-related tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and calreticulin (CALR) also were detected by capillary electrophoresis (AB 3500XL sequencer; Applied Biosystems Corporation, Foster City, CA).
Definitions of CSF3R Mutant Clone
When it was concomitant with other mutations, a CSF3R mutation was defined as a dominant clone when it had the highest or close to the highest VAF; otherwise, it was defined as a subclone. When only a CSF3R mutation was detected, it was defined as a dominant clone when the VAF was greater than or close to one-half of the proportion of myeloblast cells identified by morphology; otherwise, it was defined as a subclone.
Fusion Gene Screening
An improved, multiplex-nested, reverse transcription polymerase chain reaction protocol 11 was used to simultaneously screen 35 common fusion genes in leukemia (Supporting Table 2 ).
Follow-Up
Complete remission (CR) and relapse were defined according to the National Comprehensive Cancer Network Guidelines, version 3.2017. 12 The end of the follow-up period was September 30, 2017. Overall survival (OS) was defined as the time from diagnosis to either death or the last follow-up. Event-free survival (EFS) was defined as the time from diagnosis to the time of CR loss, recurrence or relapse, death, or the last follow-up. Relapse-free survival (RFS) was defined as the time from CR to relapse.
Statistical Analysis
Statistical analyses was performed using the SPSS software package (version 20.0; SPSS Inc, Chicago, Ill), and the significance between categorical data was calculated using chi-square tests or Fisher exact tests. P values < .05 were considered as statistically significant.
RESULTS
The Frequency and Distribution of CSF3R Mutations diagnosed with relapsed AML, 4 (8.3%) were diagnosed with secondary AML, and 1 (0.2%) was diagnosed with ALL. In total, 9 distinct CSF3R mutations were detected (Fig. 1) , and all resulted in either amino acid substitutions or protein truncations. Nineteen patients carried membrane-proximal amino acid substitutions (16 with T618I, 3 with T615A), and there were 7 cytoplasmic truncations (1 patient each with Q739*, P782Hfs*8, S783Qfs*6, S786Lfs*2, and D810*; and 2 patients with of Q749*). One of the T618I mutants contained an additional cytoplasmic Y752H mutation.
Clinical Features of CSF3R-Mutated AML and Associated Genetic Abnormalities All 13 patients with de novo AML and 8 patients with relapsed AML carried CSF3R mutations. The median age of these patients was 34 years (range, 6-65 years) and 20 years (range, 6-38 years) in the de novo and relapsed groups, respectively. There were no significant differences in sex or age distributions. Among different subtypes according to the French-AmericanBritish classification system, the proportions of patients who had M2 and M4 subtypes among those with CSF3R mutations were significantly greater than the proportions among those with wild-type CSF3R for the de (Fig. 2) .
In the overall de novo and relapsed AML cohort, CSF3R mutations appeared in 11.1% (9 of 81 patients) of those with CEBPAdm AML and in 7.6% (10 of 132 patients) of those with CBF-AML. In the de novo AML cohort, CSF3R was mutated in 13.0% (7 of 54 patients) of those with CEBPAdm-AML and in 4.3% (4 of 94 patients) of those with CBF-AML.
We observed that the CSF3R membrane-proximal missense mutation and the cytoplasmic truncated mutation were mutually exclusive. Among the 9 patients who had CSF3R-mutated CEBPAdm-AML, 8 carried a membraneproximal missense mutation (T618I or T615A), and 1 carried a cytoplasmic truncated mutation. Among the 10 patients who had CSF3R-mutated CBF-AML, 6 carried a membrane-proximal missense mutation, and 4 carried a cytoplasmic truncated mutation. There were no differences in the distribution of CSF3R membrane-proximal missense mutation and cytoplasmic truncated mutation between the groups with CEBPAdm-AML and CBF-AML.
Clone Analysis of CSF3R-Mutated de Novo and Relapsed AML
The median VAF of CSF3R in 13 patients with de novo AML was 17% (range, 3%-44%) and occurred in 9 patients as a subclone ( Table 2 ). The median VAF of Figure 1 . Colony-stimulating factor 3 receptor (CSF3R) mutations are illustrated in patients with acute leukemia. This schematic indicates the locations of CSF3R mutations identified in patients with acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). One patient with AML had both a T618I mutation and a Y752H mutation. Only 1 patient with B-cell ALL had a T618I mutation. FN indicates fibronectin; IgG, immunoglobulin G.
CSF3R Mutations in AML/Zhang et al CSF3R in 8 patients with relapsed AML was 35% (range, 4%-49%) and occurred in 7 patients as the dominant clone (Table 2) . Compared with patients who had de novo AML, CSF3R mutations were more common as dominant clones in those who had relapsed AML (30.8% vs 87.5%; P 5 .024).
Prognosis of CSF3R-Mutated de Novo and Relapsed AML
Among the 15 patients who were followed (Table 3) , the median OS and EFS of 7 patients with de novo AML were 17 months, and for the 2 relapsed cases, the RFS were 4 and 3 months, respectively; Among them, 5 underwent hematopoietic stem cell transplantation (HSCT). Until the end of follow-up, all 7 patients were in CR. The median OS, EFS, and RFS in 8 patients with relapsed AML were 18.5, 11, and 9.5 months, respectively. Among these, 4 underwent HSCT. At the end of follow-up, 3 patients were in CR, and 5 had died.
Associated Gene Abnormalities and Clonal Analysis of CSF3R-Mutated Secondary AML CSF3R mutations were detected in 4 of 48 patients (8.3%) who had a diagnosis of AML with myelodysplasiarelated changes. Two patients had AML secondary to MDS/myeloproliferative neoplasms (MDS/MPN). An analysis of the clonal evolution of the disease indicated that 1 patient carried CSF3R and IDH1 mutations at the time of initial diagnosis and later acquired the CEBPAdm mutation when progressing to AML; another patient Original Article presented with CSF3R and CEBPAdm mutations at initial diagnosis with 10% myeloblasts in bone marrow by morphologic examination, and the VAF of the CSF3R mutation was significantly higher than that of the CEBPA mutation. The remaining 2 patients had AML secondary to MDS with abnormal chromosomal karyotypes (especially associated with 27 karyotypes) without abnormalities in the RUNX1, CBFB, CEBPA, or NPM1 genes.
Target Therapy for CSF3R-Mutated AML
One patient who carried CSF3R S810Qfs*6, KIT N822K, and TP53 Q144R mutations received treatment with dasatinib. This patient achieved CR after 1 course of induction chemotherapy followed by 4 cycles of intensive chemotherapy combined with dasatinib, and his bone marrow was in continuous CR. The patient subsequently discontinued dasatinib treatment on his own accord and relapsed 10 months later. He then received 1 course of chemotherapy combined with dasatinib and achieved second CR.
CSF3R-Mutated ALL
We identified 1 patient who had B-ALL with a somatic CSF3R mutation. This patient had no history of SCN and was diagnosed with B-ALL at age 7 years. The patient relapsed 3 years and 7 months after initial treatment. CSF3R Mutations in AML/Zhang et al mutations related to congenital neutropenia were detected when we screened 275 genes associated with congenital immunodeficiency.
13 CSF3R T618I and additional sex combs like 2, transcriptional regulator (ASXL1) Q803* mutations were detected at VAFs of 50% and 51%, respectively. Neither mutation was detected in remission samples. Mutation testing was not performed at the time of initial diagnosis; therefore, for this patient, a comprehensive analysis of the evolutionary history of leukemia was not possible. The patient achieved morphologic remission through reinduction chemotherapy and then underwent allogeneic HSCT. At the time of this writing, the patient had survived for 8 months without leukemia after transplantation. DISCUSSION CSF3R somatic mutations are associated with CNL. CSF3R T618I is sufficient to drive a lethal myeloproliferative disease in a mouse bone marrow transplantation model. 14 In contrast, CSF3R cytoplasmic truncations alone do not lead to malignant transformation. [15] [16] [17] Among patients with CNL, 75% acquired CSF3R membrane-proximal missense mutations, whereas the remaining 25% carried both membraneproximal missense mutations and cytoplasmic truncation mutations. Truncation alone is rare and almost always is accompanied by T618I or T615A mutation in the same allele. 18 In the current study, we analyzed 587 patients with AML and detected CSF3R mutations in 21 patients with of de novo and relapsed AML, including 16 (76.2%) who carried membrane-proximal missense mutations (T618I or T615A) and 5 (23.8%) who carried cytoplasmic truncated mutations; these mutations were identified as mutually exclusive. The majority of CSF3R mutations (19 of 21; 90.5%) in our patients with AML were accompanied by abnormalities in either CBF genes or CEBPAdm. These results are consistent with previous studies reported by Maxson and colleagues 7 and Lavallee et al. 5 In addition, we observed that both of the 2 remaining CSF3R mutations (2 of 21; 9.5%) were accompanied by NPM1 mutations. 
Abbreviations: AA, amino acid; ALL, acute myeloid leukemia; ASXL2, additional sex combs like 2, transcriptional regulator; CEBPA, CCAAT/enhancer binding protein a; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; FAB, French-American-British classification system; FLT3-ITD, Fms-related tyrosine kinase 3-internal tandem duplication; GATA2, GATA binding protein 2; IDH2, isocitrate dehydrogenase (nicotinamide adenine dinucleotide phosphate-positive) 2, mitochondrial; JAK 3, Janus kinase 3; KIT, Kit proto-oncogene receptor tyrosine kinase; KRAS, Kirsten rat sarcoma oncogene, guanosine triphosphatase; NA, not available; NPM1, nucleophosmin 1; RUNX1, runt-related transcription factor 1; SRSF2, serine and arginine rich splicing factor 2; STAT3, signal transducer and activator of transcription 3; TET2, Tet methylcytosine dioxygenase 2; TET2, Tet methylcytosine dioxygenase 2; TP53, tumor protein 53; VAF, variant allele frequency; WT1, Wilms tumor 1. RUNX1, CBFB, and CEBPA are important transcription factors involved in myeloid differentiation. Although NPM1 is not a transcription factor, it is a transcriptional coactivator of many transcription factors. Abnormalities in these genes (RUNX1-RUNX1T1, CBFB-MYH11, biallelic CEBPA, and NPM1 mutations) lead to the blockage of myeloid differentiation and act as AML driver mutations that have been included in the WHO classification.
1 Because these genetic mutations are mutually exclusive, they may be functionally similar and share mutual regulation. [19] [20] [21] [22] It should be noted that these genetic alterations alone do not cause leukemia; additional cooperating mutations, especially in signal-transduction genes, are needed for the transformation to leukemia. CSF3R is a transcriptional target of CEBPA and is involved in JAK activation. CSF3R mutations are frequently associated with alterations of the aforementioned transcription factors in AML, as demonstrated in the current study and by others. It is possible that CSF3R mutations occur at a later stage of AML and synergistically interact with the altered transcription factors to block myeloid differentiation and/or provide a proliferation advantage to myeloblasts.
AML is clonally heterogeneous. The evolutionary pattern of CSF3R mutations in AML rarely has been studied. Fasan et al reported that CSF3R mutations were subclones (VAF, < 10%) in 5 of 7 patients with AML and disappeared at relapse in 2 patients. 23 Lavallee and colleagues reported that CSF3R mutations were dominant clones in 4 patients with CEBPAdm-AML (VAF, 37.6%). 5 We observed that the median VAF of CSF3R mutation was 17% among patients with de novo AML and 35% among those with relapsed AML; therefore, CSF3R mutations in relapsed AML are more dominant (P 5 .024). An analysis of initial diagnostic and relapse samples from 1 patient indicated that the CSF3R mutation was subclonal at initial diagnosis and then became dominant and was associated with a concurrent WT1 mutation upon relapse. We suggest that CSF3R mutations may be unstable during AML development. In addition, we observed that the clonal evolution and the pattern of concomitant mutations in CSF3R-mutated, secondary AML are different from those in primary AML. In patients who developed AML secondary to MDS/ MPN, the CSF3R mutation acted as a driver mutation and occurred before CEBPAdm. In patients who had AML secondary to MDS, both were associated with an abnormal chromosomal karyotype, especially 27.
CSF3R mutations can be used as molecular markers for therapy that targets aberrantly activated JAK or SRCkinase pathways. In vitro studies and several case reports have suggested that CNL and aCML are sensitive to JAK inhibitors. 2, 14, 24, 25 A prospective phase 2 clinical trial to evaluate the efficacy of ruxolitinib in the treatment of CNL/aCML with CSF3R mutations is underway (clinicaltrials.gov identifier NCT02092324). 26 More recently, mice transplanted with compound CSF3R mutations (membrane-proximal missense mutation and cytoplasmic truncated mutation in the same allele) did not to respond to ruxolitinib; whereas trametinib, a dual-specificity mitogen-activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor, could suppress leukemia induced by both membrane-proximal and ruxolitinib-resistant compound CSF3R mutations. 27 Thus, CSF3R mutations in patients with AML may be similarly targeted. It is important to note that CSF3R mutations appear to occur in subclones and may not act as founder mutations in the development of primary AML, which is in contrast to CNL and AML secondary to MDS/MPN. In our cohort, 1 patient who received dasatinib exhibited potential efficacy. Further studies are warranted to clarify the efficacy of targeted therapy in CSF3R-mutated AML.
Because of the limited number of patients with CSF3R-mutated AML, the prognostic significance of CSF3R mutation has not been defined. Maxson et al reported that there were no significant differences in 5-years OS, EFS, and relapse risk among 19 patients who had CSF3R-mutated and CSF3R wild-type pediatric AML. 7 In that study, the median OS and EFS of 7 patients with de novo AML were both 14 months. Two patients relapsed and then reached CR after reinduction chemotherapy and HSCT. At the time of follow-up, these 7 patients were all in CR.
CSF3R mutations have been identified primarily in myeloid malignancies and rarely in B-ALL. In 3 previous patients who had B-ALL secondary to SCN, all were diagnosed with SCN in infancy and received long-term treatment with recombinant granulocyte-colony-stimulating factor. All of those patients subsequently acquired CSF3R truncations and progressed to B-ALL at ages 12, 13, and 19 years. 17, 28, 29 The patient with B-ALL reported in the current report did not have a history of SCN and had no neutropenia-associated germline mutation. The acquired CSF3R mutation was a membrane-proximal missense mutation (T618I) and was accompanied by concurrent iAMP21, in which a genomic region of 5.1 Mb in chromosome 21 was highly amplified. 30 Although the RUNX1 gene is located in the amplified region, the current results indicate that RUNX1 is neither overexpressed nor mutated. 31, 32 It is unclear whether an increase in
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RUNX1 copy numbers was synergistic with CSF3R T618I in causing the development of B-ALL. In summary, the combination of high-throughput DNA sequencing technologies, bioinformatics, and detailed clinical and patient information, as described in this report, has provided an in-depth understanding of the nature of CSF3R mutations in AML and their interactions with other genetic abnormalities. We believe that this approach ultimately will shed light on the pathogenesis of AML, refine the classification and precise treatment of AML, and provide useful guidance for targeted therapy and disease prognosis in the future.
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